Percentage of Her2 positive cells in immunohistochemistry-equivocal (2+) invasive breast cancer and its significance as a predictive value for the amplification status

被引：0
|
作者：
Marras, V. [1 ]
Satta, G. [1 ]
Fedeli, M. A. [1 ]
Trombetta, M. [1 ]
Lako, K. [1 ]
Meloni, M. [1 ]
Fara, A. M. [1 ]
Camboni, A. C. [1 ]
Doneddu, V. [1 ]
Manca, A. [1 ]
Tanda, F. [1 ]
机构：
[1] AOU Sassari, UO Anat Patol, Sassari, Italy
来源：
VIRCHOWS ARCHIV | 2017年 / 471卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-01-034
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 50 条
  • [41] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    LABORATORY INVESTIGATION, 2019, 99
  • [42] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
    Zhao, Jing
    Krishnamurti, Uma
    Zhang, Chao
    Meisel, Jane
    Wei, Zhimin
    Suo, Aili
    Aneja, Ritu
    Li, Zaibo
    Li, Xiaoxian
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
  • [43] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    MODERN PATHOLOGY, 2019, 32
  • [44] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    MODERN PATHOLOGY, 2016, 29 : 44A - 44A
  • [45] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    LABORATORY INVESTIGATION, 2016, 96 : 44A - 44A
  • [46] Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
    Hicks, David G.
    LABMEDICINE, 2011, 42 (08): : 459 - 467
  • [47] HER2 gene amplification in patients with breast cancer with equivocal IHC results
    Meijer, Sybren L.
    Wesseling, Jelle
    Smit, Vincent T.
    Nederlof, Petra M.
    Hooijer, Gerrit K. J.
    Ruijter, Henrique
    Arends, Jan Willem
    Kliffen, Mike
    van Gorp, Joost M.
    Sterk, Lotus
    van de Vijver, Marc J.
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (12) : 1069 - 1072
  • [48] HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+Breast Cancer With Early Recurrence
    Yamashita, Hiroko
    Ishida, Naoko
    Hatanaka, Yutaka
    Hagio, Kanako
    Oshino, Tomohiro
    Takeshita, Takashi
    Kanno-Okada, Hiromi
    Shimizu, Ai
    Hatanaka, Kanako C.
    Matsuno, Yoshihiro
    ANTICANCER RESEARCH, 2020, 40 (02) : 645 - 652
  • [49] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [50] HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression
    Seo, A. -N.
    Jeong, J. -Y.
    Lee, S. -J.
    Choe, G. -Y.
    Kwak, Y. -J.
    Kim, W. -H.
    Lee, H. -S.
    VIRCHOWS ARCHIV, 2014, 465 : S223 - S223
12345